

sanofi

Project title	Improve the Skin Cancer Diagnosis Pathway and Breast Cancer Non-
Project title	Surgical Oncology model within South Yorkshire and Bassetlaw ICS Cancer Alliance.
Partner organisation/s	South Yorkshire and Bassetlaw (SYB) ICS Cancer Alliance and Sanofi
Project rationale	The SYB ICS Cancer Alliance has identified 7 priority areas in Cancer which include Skin Cancer and Breast Cancer . Both areas have to manage high numbers of activity but also deliver in a timely way. Due to the increasing demands on both services, the SYB ICS Cancer Alliance are looking at how these services work to meet current and future demands in order to sustain high quality services and ensure that patients are seen in a timely manner and have a good experience of the service.
	Skin Cancer
	The Collaborative Working Project will inform the development of a system wide Skin Cancer Optimum Rapid Diagnostic Pathway, which will reflect Rapid Diagnostic principles, promote achievement of the 28 Day Faster Diagnosis Standard but importantly, bring consistency and equity to delivery.
	The project aims to:
	 Define the Optimum Rapid Diagnostic Pathway for skin cancer reflecting end to end improvements (as required) and with a focus on addressing areas of unwarranted variation. Review and enhance the delivery of Teledermatology across SYB, exploring opportunities for a system wide, standardised operating model.
	The project objectives are:
	 To ensure equity of pathway access, provision, and experience for patients with suspicious skin lesions in SYB through reductions in unwarranted variations in care To enable clinically safe and effective risk stratified care using digital solutions and process which allow high resolution/quality images to be shared with appropriate skin cancer specialists To better understand options related to the onward delivery model for Teledermatology which optimise clinical outcomes, resource utilisation and contracting opportunities.

Collaborative Working Project Executive Summary Template

	Breast Cancer Non-Surgical Oncology model
	The Collaborative Working Project will support the Cancer Alliance to explore the Breast Non-Surgical Oncology model and how this might be improved to better address the issues from a patient and service/workforce perspective. In addition, it will provide project manager resource to the Cancer Alliance to explore the use of the 'Attend Anywhere' virtual reception function, to see whether this is an enabler to a potential change in the Breast Oncology delivery model.
	The project aims to:
	 Facilitate exploration and potential revision of the Breast Non- Surgical Oncology model across SYB. Piloting of enhanced Video Consultations as a potential change in
	the Breast Oncology delivery model.
	The project objectives are:
	 To improve the continuity of care and experience for breast cancer patients undergoing non-surgical oncological treatments To establish resiliency across the non-surgical oncology service in breast – optimising workforce and key enablers To optimise the opportunities afforded from the use of virtual receptions to deliver person centred, remote consultations To ensure patients are offered the choice of video consultations which enable an effective communication exchange without the constraints of social distancing and PPE, allow relatives to be present for discussions, reduce travel to hospital and disruption to daily routine etc.
Project period	Q4 2021 to Q2 2022
Project objectives	The collaborative working project will deliver the following predicted benefits for Patients, the NHS and Sanofi: Patients
	 To ensure equity of pathway access, provision, and experience for patients with suspicious skin lesions and continuity of care and experience for breast cancer oncology patients in South Yorkshire and Bassetlaw ensuring the right patients receive the right care, and in the right place at the right time. To support the timely and early diagnosis of skin cancer and provide personalised, risk stratified support and education.



	NHS
	 Reductions in unwarranted variations in care and increase in patients appropriately diagnosed with skin cancer in a timely manner through improved pathway through implementation of optimum rapid diagnosis skin cancer pathway and improved teledermatology service. Implementation of an improved and efficient pathway for Breast Non-Surgical Oncology. Effective utilisation of resources, workforce and capacity across skin and breast services.
	<u>Sanofi</u>
	 A better understanding of the skin pathway and service in South Yorkshire and Bassetlaw. Improved corporate reputation with relevant NHS organisations across the South Yorkshire and Bassetlaw area. As Sanofi produce medicines within this disease area if overall patient care is optimised there may be an increase in the usage of these products in line with national and local guidelines.
Contact details	Sanofi Aventis
Contact details	Sanofi Aventis Fleur Chandler Head of Market Access UK&IE
Contact details	Fleur Chandler
Contact details	Fleur Chandler Head of Market Access UK&IE Sanofi Aventis 410 Thames Valley Park Drive, Reading, Berkshire. RG6 1PT.
Contact details	Fleur Chandler Head of Market Access UK&IE Sanofi Aventis 410 Thames Valley Park Drive, Reading, Berkshire. RG6 1PT. <u>GB-patientaccess@sanofi.com</u>
Contact details	Fleur Chandler Head of Market Access UK&IE Sanofi Aventis 410 Thames Valley Park Drive, Reading, Berkshire. RG6 1PT. <u>GB-patientaccess@sanofi.com</u> <u>NHS</u>
Contact details	Fleur Chandler Head of Market Access UK&IE Sanofi Aventis 410 Thames Valley Park Drive, Reading, Berkshire. RG6 1PT. GB-patientaccess@sanofi.com <u>NHS</u> Georgia Thompson
Contact details	Fleur Chandler Head of Market Access UK&IE Sanofi Aventis 410 Thames Valley Park Drive, Reading, Berkshire. RG6 1PT. <u>GB-patientaccess@sanofi.com</u> <u>NHS</u>

